Reviewing the Manufacturing Innovations Enabling Commercial-Scale TRPs
2:30 pm - Tuesday 1st December 2026
- Discussing how isotope expertise, hot-cell infrastructure, regulatory readiness and radiopharmaceutical-specific GMP capabilities should influence CDMO selection decisions across different stages of TRP development
- Overcoming the operational risks associated with tech transfer, batch reproducibility, scheduling constraints and limited radionuclide handling capacity when partnering with external manufacturing providers
- Navigating which strategic considerations including scalability, geographic footprint, analytical capabilities and isotope supply integration are most critical for supporting future clinical and commercial growth